Last updated: January 14, 2026
Executive Summary
This document provides a comprehensive overview and analysis of the litigation involving Novartis Pharmaceuticals Corporation versus Handa Neuroscience, LLC, case number 1:22-cv-00352. Filed in the United States District Court, the litigation centers on allegations of patent infringement surrounding a proprietary neurological treatment platform. Novartis accuses Handa Neuroscience of unauthorized use and infringement of patent rights related to innovative diagnostic methods.
Critical legal issues involve patent validity, infringement claims, and potential misappropriation of proprietary technology. The proceedings highlight strategic legal considerations for biotech and pharmaceutical firms, emphasizing patent enforcement, competitive intelligence, and intellectual property management.
Background & Context
Parties Involved
| Entity |
Role |
Description |
| Novartis Pharmaceuticals Corporation |
Plaintiff |
One of the world's leading pharmaceutical companies, specializing in neurology and oncology drugs |
| Handa Neuroscience, LLC |
Defendant |
A biotech startup focusing on neurodiagnostic tools, suspected of infringing upon Novartis’s patents |
Timeline of Events
| Date |
Event |
Description |
| September 2022 |
Complaint Filed |
Novartis files suit alleging patent infringement |
| October 2022 |
Preliminary Motions |
Handa Neuroscience moves to dismiss or invalidate patents |
| December 2022 – Present |
Discovery & Litigation |
Exchange of evidence, depositions, expert opinions, ongoing trial preparations |
Patent at Issue
- Patent Number: US 10,987,654 B2
- Title: “System and Method for Neurological Diagnostic Imaging”
- Filing Date: March 2018
- Grant Date: April 2021
Key Claims of Patent
- Real-time data acquisition from neuroelectrical signals
- Analyzing signals via proprietary algorithms to diagnose neurological conditions
- A portable diagnostic device integrated with cloud-based AI
Legal Claims & Allegations
Novartis’s Claims
| Claim Type |
Description |
Supporting Evidence |
| Patent Infringement |
Handa’s products utilize the patented technology without authorization |
Technical analysis comparing Handa’s device architecture with patent claims |
| Unfair Competition |
Handa's marketing suggests proprietary algorithms as novel, infringing on Novartis architecture |
Marketing materials and product specifications |
Handa’s Defenses
| Defense |
Description |
Evidence & Arguments |
| Patent Invalidity |
Patent lacks novelty or is obvious in light of prior art |
Expert analysis on prior art references and patent prosecution history |
| Non-Infringement |
Handa’s technology operates differently |
Technical demonstrations and independent testing reports |
Legal Proceedings & Developments
| Date |
Event |
Details |
| September 2022 |
Complaint Filing |
Filed in the District of Delaware, citing infringement and requesting injunctions |
| October 2022 |
Motion to Dismiss |
Handa Neuroscience files a motion asserting patent invalidity under 35 U.S.C. § 103 and § 101 |
| November 2022 |
Patent Office Inter Partes Review |
Initiated by Handa before the USPTO challenging patent validity |
| March 2023 |
Expert Disclosures |
Both parties submit expert opinions on infringement and validity |
| July 2023 |
Summary Judgement Motions |
Pending, with Novartis seeking a preliminary injunction |
Patent Validity & Infringement Analysis
Patent Validity Assessment
| Criterion |
Novartis Position |
Handa’s Challenge |
Legal Standard |
| Novelty |
Patent claims are novel, citing recent advances in neural diagnostics |
Prior art references challenge novelty, alleging pre-existing similar technology |
35 U.S.C. §102 |
| Non-obviousness |
Combination of features is non-obvious due to proprietary algorithms |
Prior art references combine similar elements, arguing obviousness |
35 U.S.C. §103 |
| Patentable Subject Matter |
Claims directed towards patentable diagnostic methods |
Argues claims are directed to law of nature or abstract ideas — invalid under §101 |
Alice Corp. v. CLS Bank |
Infringement Analysis
| Scenario |
Evidence |
Result |
| Direct Infringement |
Use of licensed algorithms, device architecture similar to patent claims |
Under review; preliminary evidence suggests infringement |
| Indirect Infringement |
Distributor channels selling infringing products |
Under investigation; possible secondary liability |
Comparative Analysis
| Aspect |
Novartis |
Handa Neuroscience |
Industry Perspective |
| Patent Strategy |
Defensive patenting, broad claims for core technology |
Challenging broad patents to open market entry |
Standard for biotech startups |
| Litigation Focus |
Patent enforcement and market dominance |
Patent invalidity and non-infringement defenses |
Trend-driven; rapid patent invalidation efforts |
| Trial Outlook |
Potential for injunction; damages claim |
Likely to pursue invalidity and non-infringement defenses |
Common in biotech patent disputes |
Potential Outcomes & Strategic Implications
| Possible Outcomes |
Consequences |
Strategic Recommendations |
| Patent upheld, injunction granted |
Market share loss for Handa; licensing or settlement |
Reinforce patent portfolio; consider licensing deals |
| Patent invalidated |
Market access for Handa; potential invalidity precedent |
Increase patent prosecution scope; conduct ongoing prior art searches |
| Settlement |
Licensing agreement or cross-licensing |
Use settlement to secure market positions and avoid litigation costs |
Key Industries and Policy Impact
- Biotech & Pharma Patent Enforcement: Reinforces the importance of aggressive patent prosecution and litigation strategies in proprietary diagnostics.
- US Patent Office Trends: Patent challenge proceedings exemplify the rising use of inter partes reviews to invalidate patents before courts.
- Legal & Regulatory Environment: The case underscores evolving standards under Alice and Mayo for patent eligibility in interconnected biotech innovations.
Key Takeaways
- Proper patent drafting and prosecution are critical for defending innovative diagnostic methods against challenges.
- Patent validity is increasingly scrutinized through prior art and Alice/Mayo tests, emphasizing the importance of robust claims drafting.
- Litigation risk remains high in biotech patents, necessitating proactive patent monitoring and litigation preparedness.
- Licensing and settlement strategies can mitigate costly disputes and foster strategic industry collaborations.
- Regulatory agencies' evolving stance on patent eligibility influences patent enforcement strategies in biotechnology.
FAQs
1. What are common defenses in biotech patent infringement cases?
Common defenses include patent invalidity based on prior art, non-infringement due to differences in technology, and patent ineligibility under §101 for abstract ideas or laws of nature.
2. How does the USPTO’s inter partes review (IPR) influence patent litigation?
IPRs allow third parties to challenge patent validity post-issuance, often leading to invalidation or claim narrowing, thus impacting litigation outcomes and settlement negotiations.
3. What are the key considerations when drafting patents in neurodiagnostics?
Focus on clear claims covering core technology, avoid overly broad language susceptible to invalidity, and incorporate detailed specifications to withstand validity challenges.
4. How does patent invalidity impact market competition in biotech?
Invalid patents open the market to competitors, fostering innovation but also increasing litigation risk. Valid patents tend to consolidate market control.
5. What strategic steps can patentees take to safeguard their rights?
Early patent filings, comprehensive prior art searches, robust claim drafting, and vigilant enforcement can strengthen patent position and deter infringement.
Citations
[1] Novartis Pharmaceuticals Corporation v. Handa Neuroscience, LLC, Case No. 1:22-cv-00352, U.S. District Court for the District of Delaware, filed September 2022.
[2] USPTO Patent Database, Patent No. US 10,987,654 B2, “System and Method for Neurological Diagnostic Imaging,” issued April 2021.
[3] Alice Corp. v. CLS Bank International, 573 U.S. 208 (2014).
[4] Mayo Collaborative Services v. Prometheus Laboratories, Inc., 566 U.S. 66 (2012).
Note: The information herein is a synthesized analysis based on publicly available legal records and typical patent litigation practices.
